Crescent Biopharma, Inc.
CBIO
$10.35
-$0.75-6.76%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/18/2026
-
Tickeron - Technical Analysis
3/18/2026
-
Tickeron - Technical Analysis
3/18/2026
-
Tickeron - Technical Analysis
3/17/2026
-
Tickeron - Stocks
3/17/2026
-
Tickeron - Stocks
3/11/2026
-
Tickeron - Stocks
3/10/2026
-
Ticker Report
3/7/2026
-
Tickeron - Stocks
3/7/2026
-
MarketBeat
3/6/2026
-
Globe Newswire
3/6/2026
-
Ticker Report
3/6/2026
-
Tickeron - Stocks
3/5/2026
-
Tickeron - Stocks
3/3/2026
-
Tickeron - Stocks
3/2/2026
-
MarketBeat
3/2/2026
-
TipRanks Financial Blog
2/28/2026
-
Simply Wall St
2/27/2026
-
MarketBeat
2/26/2026
-
TipRanks Financial Blog
2/26/2026
-
TipRanks Financial Blog
2/26/2026
-
The Fly
2/26/2026
-
Globe Newswire
2/26/2026
-
MarketBeat
2/26/2026
-
Tickeron - Stocks
2/24/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, February 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Jul 27 and 31 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 460 5595
Address
300 Fifth Avenue
Waltham, MA 02451
Waltham, MA 02451
Country
Year Founded
Business Description
Sector
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a...
more